Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicamtiv in symptomatic genetic and familial dilated cardiomyopathy
NL-OMON60950Phase 3Recruiting
- Sponsor
- Kardigan
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of danicamtiv in dilated cardiomyopathy (DCM) and familial dilated cardiomyopathy (FDCM), sponsored by Kardigan. Primary endpoints: Change from baseline to Week 26 in left atrial function index and Change from baseline to Week 26 in peak oxygen consumption. Started Jun 2026; status: recruiting.
02
Drugs
danicamtiv
03
Conditions
dilated cardiomyopathy (DCM)familial dilated cardiomyopathy (FDCM)
Beyond the preview
Go deeper on NL-OMON60950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60950.